Dr. Michael Kopach earned a Ph. D. in Organic chemistry from the University of Virginia in 1995 under the guidance of Prof. W.D. Harman. He then completed postdoctoral studies in natural product synthesis at Colorado State University with Professor A. I. Meyers. Dr. Kopach began his industrial career in 1997 at Roche where his primary responsibilities included development and implementation of commercial processes for Nelfinavir, Xenical and Enfuvirtide - the first synthetic peptide produced on tonnage scale. In 2001, Dr. Kopach joined Eli Lilly and Company and has led several small molecule phase 1 to phase 3 R&D projects. Throughout his industrial career, Dr. Kopach has led research teams applying green chemistry principles to product research and development, and has published several collaborative articles in this field. For the past decade, Dr. Kopach has represented Eli Lilly and Company at the ACS Green Chemistry Institute® Pharmaceutical Roundtable including serving two year terms as co-chairs from 2011-2013 then another from 2017 - 2019. After a fourteen-year career within Lilly Small Molecule R&D, Mike now has responsibility for multiple commercial synthetic peptide projects.